Abstract
Background. Minor histocompatibility antigen (mHag) induces and mounts graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Among several mHags, HA-1 is one that acts alone and is the most studied. It is suggested that HA-1 may be one of the immunodominant antigens inducing not only graft-versus-host disease but also graft-versusmalignancy effects. There are some reports that mHag HA-1-specific cytotoxic T lymphocytes generated from an HA-1-negative donor can lyse HA-1-positive leukemic cells. However, the tissue distribution of HA-1 has been described as restricted to the cells of the hematopoietic lineage. Methods. We examined the HA-1 expression in peripheral blood mononuclear cells (PBMNC), leukemia/ lymphoma cell lines, solid tumor cell lines, and paired samples of tumor and normal tissues from individual cancer patients by quantitative reverse-transcription polymerase chain reaction. Results. We found that mRNA of HA-1 is expressed in all leukemia/lymphoma cell lines and PBMNC. Most of the leukemia/lymphoma cell lines have the same levels of HA-1 expression as a leukemia/lymphoma cell line, Raji. The expression levels of human PBMNC were 14to 19-fold higher than those of Raji. Among 32 solid tumor cell lines, 7 showed >50% expression levels compared with Raji. Conclusions. HA-1 expression in the mRNA level is higher in cells of hematopoietic origin, but this tissue distribution is not strictly restricted. Some solid tumor cells and tissues express HA-1 gene equal to hematopoietic cells.
| Original language | English |
|---|---|
| Pages (from-to) | 1137-1141 |
| Number of pages | 5 |
| Journal | Transplantation |
| Volume | 73 |
| Issue number | 7 |
| Publication status | Published - Apr 15 2002 |
Fingerprint
ASJC Scopus subject areas
- Transplantation
- Immunology
Cite this
Expression of minor histocompatibility antigen, HA-1, in solid tumor cells. / Fujii, Nobuharu; Hiraki, Akio; Ikeda, Kazuma; Ohmura, Yasushi; Nozaki, Isao; Shinagawa, Katsuji; Ishimaru, Fumihiko; Kiura, Katsuyuki; Shimizu, Nobuyoshi; Tanimoto, Mitsune; Harada, Mine.
In: Transplantation, Vol. 73, No. 7, 15.04.2002, p. 1137-1141.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Expression of minor histocompatibility antigen, HA-1, in solid tumor cells
AU - Fujii, Nobuharu
AU - Hiraki, Akio
AU - Ikeda, Kazuma
AU - Ohmura, Yasushi
AU - Nozaki, Isao
AU - Shinagawa, Katsuji
AU - Ishimaru, Fumihiko
AU - Kiura, Katsuyuki
AU - Shimizu, Nobuyoshi
AU - Tanimoto, Mitsune
AU - Harada, Mine
PY - 2002/4/15
Y1 - 2002/4/15
N2 - Background. Minor histocompatibility antigen (mHag) induces and mounts graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Among several mHags, HA-1 is one that acts alone and is the most studied. It is suggested that HA-1 may be one of the immunodominant antigens inducing not only graft-versus-host disease but also graft-versusmalignancy effects. There are some reports that mHag HA-1-specific cytotoxic T lymphocytes generated from an HA-1-negative donor can lyse HA-1-positive leukemic cells. However, the tissue distribution of HA-1 has been described as restricted to the cells of the hematopoietic lineage. Methods. We examined the HA-1 expression in peripheral blood mononuclear cells (PBMNC), leukemia/ lymphoma cell lines, solid tumor cell lines, and paired samples of tumor and normal tissues from individual cancer patients by quantitative reverse-transcription polymerase chain reaction. Results. We found that mRNA of HA-1 is expressed in all leukemia/lymphoma cell lines and PBMNC. Most of the leukemia/lymphoma cell lines have the same levels of HA-1 expression as a leukemia/lymphoma cell line, Raji. The expression levels of human PBMNC were 14to 19-fold higher than those of Raji. Among 32 solid tumor cell lines, 7 showed >50% expression levels compared with Raji. Conclusions. HA-1 expression in the mRNA level is higher in cells of hematopoietic origin, but this tissue distribution is not strictly restricted. Some solid tumor cells and tissues express HA-1 gene equal to hematopoietic cells.
AB - Background. Minor histocompatibility antigen (mHag) induces and mounts graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Among several mHags, HA-1 is one that acts alone and is the most studied. It is suggested that HA-1 may be one of the immunodominant antigens inducing not only graft-versus-host disease but also graft-versusmalignancy effects. There are some reports that mHag HA-1-specific cytotoxic T lymphocytes generated from an HA-1-negative donor can lyse HA-1-positive leukemic cells. However, the tissue distribution of HA-1 has been described as restricted to the cells of the hematopoietic lineage. Methods. We examined the HA-1 expression in peripheral blood mononuclear cells (PBMNC), leukemia/ lymphoma cell lines, solid tumor cell lines, and paired samples of tumor and normal tissues from individual cancer patients by quantitative reverse-transcription polymerase chain reaction. Results. We found that mRNA of HA-1 is expressed in all leukemia/lymphoma cell lines and PBMNC. Most of the leukemia/lymphoma cell lines have the same levels of HA-1 expression as a leukemia/lymphoma cell line, Raji. The expression levels of human PBMNC were 14to 19-fold higher than those of Raji. Among 32 solid tumor cell lines, 7 showed >50% expression levels compared with Raji. Conclusions. HA-1 expression in the mRNA level is higher in cells of hematopoietic origin, but this tissue distribution is not strictly restricted. Some solid tumor cells and tissues express HA-1 gene equal to hematopoietic cells.
UR - http://www.scopus.com/inward/record.url?scp=0037091033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037091033&partnerID=8YFLogxK
M3 - Article
C2 - 11965046
AN - SCOPUS:0037091033
VL - 73
SP - 1137
EP - 1141
JO - Transplantation
JF - Transplantation
SN - 0041-1337
IS - 7
ER -